Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Moskowitz

Showing results (271-280 of 280) with videos related to

Pageof 28
Sort By:
You have reached the last page of results.This site can display upto 280 results.
Blood Cancer Discovery|February 1, 2023
Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg CellsFrancesco Maura, Bachisio Ziccheddu, Jenny Z Xiang, et al.
Blood|July 27, 2016
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphomaAnita Kumar, Carla Casulo, Joachim Yahalom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2021
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin LymphomaAnita Kumar, Carla Casulo, Ranjana H Advani, et al.
Blood Cancer Journal|June 14, 2018
Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assayAndrew M Intlekofer, Erel Joffe, Connie L Batlevi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2017
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell LymphomaJacob D Soumerai, Andrew D Zelenetz, Craig H Moskowitz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 13, 2015
Hodgkin lymphoma, version 2.2015Richard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2018
NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018Richard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 7, 2017
Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in OncologyRichard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2021
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin LymphomaAlison J Moskowitz, Gunjan Shah, Heiko Schöder, et al.
Cancer Discovery|June 17, 2017
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS LymphomaChristian Grommes, Alessandro Pastore, Nicolaos Palaskas, et al.
Pageof 28

Showing results (271-280 of 280) with videos related to

Sort By:
Pageof 28
You have reached the last page of results.This site can display upto 280 results.
Blood Cancer Discovery|February 1, 2023
Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg CellsFrancesco Maura, Bachisio Ziccheddu, Jenny Z Xiang, et al.
Blood|July 27, 2016
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphomaAnita Kumar, Carla Casulo, Joachim Yahalom, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 28, 2021
Brentuximab Vedotin Combined With Chemotherapy in Patients With Newly Diagnosed Early-Stage, Unfavorable-Risk Hodgkin LymphomaAnita Kumar, Carla Casulo, Ranjana H Advani, et al.
Blood Cancer Journal|June 14, 2018
Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assayAndrew M Intlekofer, Erel Joffe, Connie L Batlevi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 19, 2017
The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell LymphomaJacob D Soumerai, Andrew D Zelenetz, Craig H Moskowitz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 13, 2015
Hodgkin lymphoma, version 2.2015Richard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|March 11, 2018
NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018Richard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 7, 2017
Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in OncologyRichard T Hoppe, Ranjana H Advani, Weiyun Z Ai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 25, 2021
Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin LymphomaAlison J Moskowitz, Gunjan Shah, Heiko Schöder, et al.
Cancer Discovery|June 17, 2017
Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS LymphomaChristian Grommes, Alessandro Pastore, Nicolaos Palaskas, et al.
Pageof 28